Allen D. Roses
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Allen D. Roses has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Ann M. Saunders
Departments of Medicine (Neurology) and Neurobiology, Duke University Medical Center, Durham, North Carolina 27710, USA
1 shared publication
Latest Publications
- 1 September 1997
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 826 (1) , 200-212
ApoE, Alzheimer's Disease, and Recovery from Brain Stressa
Apolipoprotein E (APOE, gene; ApoE, protein) is the major genetic susceptibility locus for the common forms of Alzheimer's disease (AD). There are three common polymorphisms in the population: ɛ2, ɛ3, and ɛ4. The inheritance of each dose of ɛ4 increases the risk and lowers the age of onset distribution for AD; ɛ2 lowers the risk and increases the age of onset distribution. APOE‐ɛ4 has a high positive predictive value for AD, and is clinically useful as an adjunct in the early diagnosis of cognitively impaired patients. The APOE alleles have also been associated with risk of AD with head injury, intraneuronal localization of ApoE in animal stroke models, recovery of function after intracerebral hemorrhage, and recovery of psychological parameters after general cardiac anesthesia. A multifunctional role of ApoE in the brain implicates isoform‐specific differences in interactions with several brain proteins including Añ, tau, and MAP‐2. Intraneuronal ApoE is increased temporally and in relevant neurons in AD as a function of APOE genotype. Decreased glucose metabolism can be demonstrated by PET imaging in subjects two decades before the median age of onset as a function of APOE genotype. ApoE isoforms may also have different effects as antioxidants. The risk of stroke and vascular dementia has not been confirmed in neuropathological series to be related to specific APOE genotypes.
- 1 September 1997
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 826 (1) , 200-212
ApoE, Alzheimer's Disease, and Recovery from Brain Stressa
Apolipoprotein E (APOE, gene; ApoE, protein) is the major genetic susceptibility locus for the common forms of Alzheimer's disease (AD). There are three common polymorphisms in the population: ɛ2, ɛ3, and ɛ4. The inheritance of each dose of ɛ4 increases the risk and lowers the age of onset distribution for AD; ɛ2 lowers the risk and increases the age of onset distribution. APOE‐ɛ4 has a high positive predictive value for AD, and is clinically useful as an adjunct in the early diagnosis of cognitively impaired patients. The APOE alleles have also been associated with risk of AD with head injury, intraneuronal localization of ApoE in animal stroke models, recovery of function after intracerebral hemorrhage, and recovery of psychological parameters after general cardiac anesthesia. A multifunctional role of ApoE in the brain implicates isoform‐specific differences in interactions with several brain proteins including Añ, tau, and MAP‐2. Intraneuronal ApoE is increased temporally and in relevant neurons in AD as a function of APOE genotype. Decreased glucose metabolism can be demonstrated by PET imaging in subjects two decades before the median age of onset as a function of APOE genotype. ApoE isoforms may also have different effects as antioxidants. The risk of stroke and vascular dementia has not been confirmed in neuropathological series to be related to specific APOE genotypes.
- 1 May 1997
- Published by Springer Nature in neurogenetics
- Vol. 1 (1) , 3-11
A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease
Apolipoprotein E (APOE) polymorphisms are associated with variable risk and age of onset distributions for the common form of Alzheimer disease. Clinical genetic applications of APOE genotyping differ from those of family-specific mutations because the APOE genotypes are universally distributed in all populations, with ethnic and racial variations in relative allele frequencies. The association of a common disease affecting millions of people with genetic risk factors provides a new paradigm for understanding disease pathogenesis and an opportunity to focus on relevant genetic mechanisms. Clinical applications of APOE genotype information are based on epidemiological principles, rather than family-specific genetic counseling. At the present time it is not possible to predict when or if any individual will develop AD. Likewise, no APOE genotype provides escape from risk. However, an impending ethical and social dilemma is on the near horizon. When additional susceptibility polymorphisms are found, for example within a recently reported linkage to a chromosome 12 region, disease prediction may be possible for millions of unaffected individuals at a time when preventive therapies are not yet available. This impeding capability should be a wake-up call for anticipating social, ethical, and legal problems. It differs from the current model of family specific mutations because, rather than affecting a relatively small population at risk, millions of people will be capable of receiving favorable or unfavorable prognostic information. The association of common polymorphisms with complex diseases finds its first example in APOE and AD. Just as the linkage search for other susceptibility genes can be modelled after AD, the medical, ethical, social, and legal implications of this paradigm can serve as a template for other complex disease loci being actively sought by industry and in academic laboratories.
- 1 May 1997
- Published by Springer Nature in neurogenetics
- Vol. 1 (1) , 3-11
A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease
Apolipoprotein E (APOE) polymorphisms are associated with variable risk and age of onset distributions for the common form of Alzheimer disease. Clinical genetic applications of APOE genotyping differ from those of family-specific mutations because the APOE genotypes are universally distributed in all populations, with ethnic and racial variations in relative allele frequencies. The association of a common disease affecting millions of people with genetic risk factors provides a new paradigm for understanding disease pathogenesis and an opportunity to focus on relevant genetic mechanisms. Clinical applications of APOE genotype information are based on epidemiological principles, rather than family-specific genetic counseling. At the present time it is not possible to predict when or if any individual will develop AD. Likewise, no APOE genotype provides escape from risk. However, an impending ethical and social dilemma is on the near horizon. When additional susceptibility polymorphisms are found, for example within a recently reported linkage to a chromosome 12 region, disease prediction may be possible for millions of unaffected individuals at a time when preventive therapies are not yet available. This impeding capability should be a wake-up call for anticipating social, ethical, and legal problems. It differs from the current model of family specific mutations because, rather than affecting a relatively small population at risk, millions of people will be capable of receiving favorable or unfavorable prognostic information. The association of common polymorphisms with complex diseases finds its first example in APOE and AD. Just as the linkage search for other susceptibility genes can be modelled after AD, the medical, ethical, social, and legal implications of this paradigm can serve as a template for other complex disease loci being actively sought by industry and in academic laboratories.
- 1 October 1996
- Published by Elsevier in Current Opinion in Neurobiology
- Vol. 6 (5) , 644-650
The Alzheimer diseases
- 1 October 1996
- Published by Elsevier in Current Opinion in Neurobiology
- Vol. 6 (5) , 644-650
The Alzheimer diseases